- Home
- YOSH vs APVO Comparison
YOSH vs APVO Comparison
Compare YOSH & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- APVO
- Stock Information
- Founded
- YOSH 2016
- APVO 2016
- Country
- YOSH United States
- APVO United States
- Employees
- YOSH N/A
- APVO N/A
- Industry
- YOSH Restaurants
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- APVO Health Care
- Exchange
- YOSH Nasdaq
- APVO Nasdaq
- Market Cap
- YOSH 5.0M
- APVO 5.4M
- IPO Year
- YOSH 2022
- APVO N/A
- Fundamental
- Price
- YOSH $8.76
- APVO $3.47
- Analyst Decision
- YOSH
- APVO Strong Buy
- Analyst Count
- YOSH 0
- APVO 1
- Target Price
- YOSH N/A
- APVO $296.00
- AVG Volume (30 Days)
- YOSH 187.8K
- APVO 44.0K
- Earning Date
- YOSH 03-31-2025
- APVO 03-04-2025
- Dividend Yield
- YOSH N/A
- APVO N/A
- EPS Growth
- YOSH N/A
- APVO N/A
- EPS
- YOSH N/A
- APVO N/A
- Revenue
- YOSH $11,652,880.00
- APVO N/A
- Revenue This Year
- YOSH N/A
- APVO N/A
- Revenue Next Year
- YOSH N/A
- APVO N/A
- P/E Ratio
- YOSH N/A
- APVO N/A
- Revenue Growth
- YOSH 25.97
- APVO N/A
- 52 Week Low
- YOSH $2.71
- APVO $3.01
- 52 Week High
- YOSH $16.50
- APVO $399.60
- Technical
- Relative Strength Index (RSI)
- YOSH 54.11
- APVO 33.42
- Support Level
- YOSH $3.83
- APVO $3.20
- Resistance Level
- YOSH $16.50
- APVO $3.65
- Average True Range (ATR)
- YOSH 2.79
- APVO 0.34
- MACD
- YOSH 0.29
- APVO 0.01
- Stochastic Oscillator
- YOSH 41.36
- APVO 31.51
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.